All In Biotech

Drug Trial Radar · NCT07949669

A Study of HLX105 in Patients With Advanced or Metastatic Solid Tumors

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX105 (Anti-PD-1 Antibody-IL-2 Variant Fusion Protein) in Advanced/Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Nov 30, 2027

Study completion Nov 30, 2028

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Nov 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, first-in-human, Phase 1 study of HLX105, an anti-PD-1 antibody-IL-2 variant fusion protein, in adults with advanced or metastatic solid tumors that have progressed after standard treatment or for which no standard treatment is available. The main purpose is to evaluate the safety and tolerability of HLX105 and determine its maximum tolerated dose. The study will also assess how the body processes HLX105, whether antibodies against HLX105 develop, preliminary antitumor activity, and changes in immune cells and other biomarkers.

Conditions

  • Solid Tumor (Phase I)

Interventions

  • HLX105Drug

    HLX105 will be administered as an intravenous(IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT)Time frame: The first 21 days starting with the first dose for participants dosed every 3 weeks, and the first 28 days starting with the first dose for participants dosed every 2 weeks.
  2. Maximum tolerated dose(MTD)Time frame: Up to approximately 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.